NASDAQ:DRNA Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$38.22▼$38.2250-Day Range$37.81▼$38.2552-Week Range$19.06▼$40.14VolumeN/AAverage Volume1.34 million shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Dicerna Pharmaceuticals alerts: Email Address Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA)Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. DRNA Stock News HeadlinesMay 25, 2023 | fool.comArrowhead Pharmaceuticals (NASDAQ: ARWR)February 16, 2023 | thestreet.com'Mad Money' Lightning Round: I'm Staying Away From Five BelowJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 7, 2023 | benzinga.comBiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News SummaryJanuary 26, 2023 | marketwatch.comMyc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028January 19, 2023 | finance.yahoo.comWe Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business GrowthJanuary 14, 2022 | ca.finance.yahoo.comDRNA Jan 2022 22.500 callJanuary 14, 2022 | ca.finance.yahoo.comDRNA Jul 2022 40.000 call(CONTRJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.December 28, 2021 | finance.yahoo.comNovo Nordisk Announces Completion of Dicerna Pharmaceuticals AcquisitionNovember 19, 2021 | prnewswire.comDICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNANovember 19, 2021 | finance.yahoo.comSHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.November 18, 2021 | finance.yahoo.comDICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the FirmNovember 18, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo NordiskNovember 18, 2021 | finance.yahoo.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.November 18, 2021 | barrons.comDicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 BillionNovember 18, 2021 | finance.yahoo.comUPDATE 3-Denmark's Novo Nordisk to buy Dicerna Pharma for $3.3 billionNovember 12, 2021 | finance.yahoo.comDicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021See More Headlines Receive DRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:DRNA CUSIPN/A CIK1399529 Webwww.dicerna.com Phone(617) 621-8097Fax617-612-6298Employees302Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,750,000.00 Net Margins-64.53% Pretax Margin-63.82% Return on Equity-103.08% Return on Assets-16.58% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual Sales$164.31 million Price / Sales18.17 Cash FlowN/A Price / Cash FlowN/A Book Value$1.84 per share Price / Book20.77Miscellaneous Outstanding Shares78,129,000Free Float70,160,000Market Cap$2.99 billion OptionableOptionable Beta0.80 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDouglas M. FambroughPresident, Chief Executive Officer & DirectorJames B. WeissmanChief Operating Officer & Executive Vice PresidentDouglas W. PagánChief Financial OfficerBob D. BrownChief Scientific OfficerShreeram AradhyeChief Medical Officer & Executive Vice PresidentKey CompetitorsRocket PharmaceuticalsNASDAQ:RCKTArbutus BiopharmaNASDAQ:ABUSY-mAbs TherapeuticsNASDAQ:YMABHeron TherapeuticsNASDAQ:HRTXMersana TherapeuticsNASDAQ:MRSNView All Competitors DRNA Stock Analysis - Frequently Asked Questions How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) released its quarterly earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.19. The biopharmaceutical company earned $62.95 million during the quarter, compared to the consensus estimate of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO? 35 employees have rated Dicerna Pharmaceuticals Chief Executive Officer Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among the company's employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Dicerna Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). This page (NASDAQ:DRNA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dicerna Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.